On Monday Taysha Gene Therapies Inc (NASDAQ: TSHA) opened lower -10.08% from the last session, before settling in for the closing price of $4.96. Price fluctuations for TSHA have ranged from $1.05 to $5.51 over the past 52 weeks.
Annual sales at Healthcare sector company slipped by -63.99% over the past five years. Company’s average yearly earnings per share was noted 3.33% at the time writing. With a float of $222.28 million, this company’s outstanding shares have now reached $272.73 million.
Taysha Gene Therapies Inc (TSHA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 18.52%, while institutional ownership is 87.00%. The most recent insider transaction that took place on Sep 22 ’25, was worth 30,479. Before that another transaction happened on Sep 10 ’25, when Company’s President and Head of R&D sold 200,000 for $3.23, making the entire transaction worth $646,000. This insider now owns 1,006,439 shares in total.
Taysha Gene Therapies Inc (TSHA) Latest Financial update
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.07 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.09) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 3.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 3.09% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 12.48. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 150.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.09 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Taysha Gene Therapies Inc (NASDAQ: TSHA) saw its 5-day average volume 3.94 million, a positive change from its year-to-date volume of 3.88 million. As of the previous 9 days, the stock’s Stochastic %D was 42.93%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 67.83%, which indicates a significant increase from 31.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.39 in the past 14 days, which was higher than the 0.23 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.91, while its 200-day Moving Average is $2.57. Nevertheless, the first resistance level for the watch stands at $4.69 in the near term. At $4.92, the stock is likely to face the second major resistance level. The third major resistance level sits at $5.28. If the price goes on to break the first support level at $4.10, it is likely to go to the next support level at $3.74. The third support level lies at $3.51 if the price breaches the second support level.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 272,795K shares outstanding in the company with a market cap of 1.22 billion. Presently, the company’s annual sales total 8,330 K according to its annual income of -89,300 K. Last quarter, the company’s sales amounted to 1,990 K and its income totaled -26,880 K.
